Allerfex

Quick links to important sections

Allerfex

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allerfex

Quick Facts

Property Description
Active ingredient Fexofenadine hydrochloride
Form Oral tablet or liquid suspension
Pharmacological class Antihistamine (Second-generation)
Common purpose Relief of general allergy symptoms
Origin Synthetic metabolite

What Type of Medicine is Allerfex? (Definition and Classification)

Allerfex is a trade name for a medication containing the active ingredient fexofenadine hydrochloride, which belongs to the class of drugs known as antihistamines. It is classified as a second-generation antihistamine, a synthetic agent developed to target allergy responses effectively.

Fexofenadine is specifically defined as a selective peripheral H1 receptor antagonist. This medicine is clinically recognized for its ability to target peripheral histamine receptors, which means it helps ease discomfort caused by histamine without crossing into the central nervous system significantly. The second-generation design is a key feature, allowing for effective allergy relief while reducing the likelihood of drowsiness often associated with older antihistamines.

Composition and Form: Single-Ingredient Antihistamine

Allerfex is designed as a single-ingredient medicine, containing only fexofenadine hydrochloride, distinguishing it from combination products that include decongestants or pain relievers. This brand is typically available as an oral tablet and is often marketed as a non-prescription (OTC) medication in many countries.

The brand may also offer an oral suspension (liquid) designed for pediatric use or for patients who have difficulty swallowing pills, providing a specific benefit for families. Its single-ingredient composition ensures that patients are taking only the specific compound needed to target the allergic response without the effects of unnecessary added components.

Why Is Allerfex Used for Allergies? (General Purpose)

The general purpose of Allerfex is to provide relief from common allergy symptoms by functioning as a histamine blocker. It works by blocking the activity of histamine, a substance the body releases during an allergic reaction that triggers uncomfortable symptoms.

As a histamine blocker, Allerfex is typically used when a person is experiencing common symptoms such as frequent sneezing, itchy/watery eyes, and a runny nose. This action allows Allerfex to manage these manifestations effectively, serving as a non-sedating option for allergy relief.

Regulatory References

  1. Fexofenadine: MedlinePlus Drug Information

What side effects are possible with Allerfex?

Possible side effects and safety information

The safety profile of Allerfex (fexofenadine) is officially documented by regulatory agencies, classifying potential adverse reactions by frequency and physiological system.

Official Adverse Reaction Frequencies

Classification Common Effects Rare Effects (Frequency Not Known)
Frequency ge 1/100 Post-Marketing Reports
Examples Headache, Drowsiness, Dizziness, Nausea, Fatigue Insomnia, Nervousness, Sleep disorders, Palpitations, Tachycardia

Common Effects primarily involve the Nervous System and Gastrointestinal System, including documented effects such as headache, dizziness, and nausea.

Serious Adverse Reactions

The most significant, though rare, reactions documented in official labeling are severe Hypersensitivity Reactions. These can include manifestations such as Angioedema (swelling of the face or throat), Systemic Anaphylaxis, chest tightness, and dyspnoea (difficulty breathing).

Population-Specific Safety Considerations

Regulatory documents include specific notes for certain patient populations:

  • Pediatric Patients (6 months to 5 years): Reports indicate a higher frequency of vomiting, diarrhea, and somnolence in this age group.
  • Elderly Patients and those with Renal Impairment: Caution is advised because altered kidney function can prolong the drug's half-life, which may necessitate careful consideration of exposure.
  • Pregnancy and Lactation: Use is generally not recommended unless deemed essential, as fexofenadine is known to pass into human breast milk.

High-Level Safety Constraints

The medicine is contraindicated in individuals with a known hypersensitivity to fexofenadine. Furthermore, the official label advises that co-administration with aluminum- or magnesium-containing antacids or with certain fruit juices (such as grapefruit, orange, or apple) can reduce the absorption of fexofenadine, which impacts the medicine's overall exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe overdose reports for fexofenadine (Allerfex) as infrequent and containing limited information. Nevertheless, the official labeling provides specific guidance on reported symptoms and required actions.


Documented Overdose Symptoms and Management

The most commonly reported clinical manifestations in cases of human overdose have included effects on the central nervous system and mucous membranes, specifically:

  • Dizziness
  • Drowsiness
  • Dry Mouth

In the event of an overdose, a specific and immediate response is required according to government-authorized product information. The official protocol involves:

  1. Seeking Immediate Medical Attention: Get medical help or contact a Poison Control Center right away, as stated in the product instructions.
  2. Supportive Treatment: Symptomatic and supportive treatment for the patient is recommended.
  3. Decontamination: Standard measures should be considered to remove any unabsorbed drug from the body.

It is important to note that hemodialysis does not effectively remove fexofenadine from the blood and is therefore not considered a beneficial treatment measure for overdose.

Therapeutic Uses of Allerfex

What Allerfex treats: main uses and benefits

Allerfex is a medication commonly used across conditions presenting with acute episodes to provide targeted symptomatic support. The medication is generally applied across domains where additional symptomatic support is needed for conditions like seasonal and perennial allergic rhinitis (hay fever) and Chronic Idiopathic Urticaria (CIU, or chronic hives).

Symptom Management and Patient Support

This medication helps address symptom clusters that may become intense or disruptive, such as sneezing, runny nose, itchy eyes, and pruritus (skin itching). It is applied in addressing these symptoms in scenarios where additional management of discomfort is required. The key benefit is offering symptomatic relief that helps patients cope more steadily during periods of heightened symptoms and may assist with maintaining functional stability.


Quick Fact: Support for Allergic Discomfort
Primary Benefit Symptomatic support for histamine-driven distress
Target Symptoms Nasal, ocular, and skin irritation clusters
Typical Use Context Episodes of heightened symptoms (e.g., pollen season)
Soft Benefit Supportive management for functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility and Official Restrictions

The eligibility profile for Allerfex (Fexofenadine hydrochloride) is formally defined by regulatory authorities based on age, known allergies, organ function, and specific physiological states.

Absolute Contraindications

Use of Allerfex is strictly contraindicated in any patient with a known hypersensitivity to the active ingredient, fexofenadine, or to any of the product's excipients. Additionally, specific dosage forms, such as orally disintegrating tablets, are contraindicated for patients with phenylketonuria (PKU) due to the presence of phenylalanine in those formulations.

Age and Conditional Use

Use is established for adults and adolescents. Depending on the formulation, pediatric use is approved for children as young as 6 months of age for certain indications; however, safety and efficacy are not established in infants below 6 months.

Conditional use is required for patients with decreased renal function (kidney impairment) and hepatic impairment (liver problems), as the body's clearance of the medicine may be altered. Caution is also advised for older adults (aged 65 and above) and for individuals with a history of cardiovascular disease.

Pregnancy and Lactation Status

Regulatory documents classify use during pregnancy and lactation as generally not recommended. This position is based on the lack of adequate human data in pregnancy and the documented finding that fexofenadine is excreted into breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for fexofenadine (Allerfex) is defined by interactions that alter its systemic exposure ( AUC/ C max) rather than through metabolic pathways like the CYP enzyme system. Regulatory documents classify these as clinically significant exposure modifications.

Exposure-Modifying Drug-Drug Interactions

Classification Interacting Medicines Interaction Outcome
Transporter Inhibition Erythromycin, Ketoconazole Increases fexofenadine plasma concentration by 2 to 3 times.
Transporter Induction Apalutamide Decreases fexofenadine systemic exposure.

The co-administration of fexofenadine with transport inhibitors such as Erythromycin or Ketoconazole is documented to significantly increase the plasma concentration of the antihistamine. Conversely, the co-administration of Apalutamide is officially noted to decrease fexofenadine exposure. No combination is formally designated as contraindicated in the regulatory labeling.

Interactions with Food and Other Products

  • Aluminum and Magnesium Antacids: Co-administration with antacids containing aluminum or magnesium hydroxide gels is documented to decrease fexofenadine bioavailability. Regulatory documents require a minimum separation of two hours between the administration of fexofenadine and these antacids.
  • Fruit Juices: Juices such as grapefruit, orange, and apple are documented to reduce fexofenadine systemic exposure and should be avoided at the time of administration, as they interfere with the drug's absorption.

Population-Specific Caution

Fexofenadine is primarily eliminated via the kidneys. Regulatory sources include a caution that effects may be increased in patients with renal impairment due to reduced drug clearance.

Mechanism of Action

How Allerfex Works

Allerfex's action involves the targeted interaction with specific pathways involved in mediator release, resulting in the modulation of H1 receptor-driven signaling. The drug is defined by its selective mechanism, which avoids significant interaction with alternative signaling pathways.


Targeted Modulation of Peripheral H1 Receptor Signaling

This domain covers the drug's primary action as a selective antagonist at peripheral histamine H1 receptors (, H1 R), found predominantly on endothelial cells, smooth muscle, and peripheral nerves. By binding to these receptors, Allerfex interrupts the molecular steps that initiate the signaling cascade, which alters the downstream physiological consequences of histamine-receptor activation on peripheral tissues.


Selective Absence of Central Nervous System (CNS) Activity

This mechanistic domain reflects the drug's limited ability to cross the blood-brain barrier (BBB) due to its structural properties. This results in minimal central H1 receptor engagement and the preferential modulation of peripheral signaling pathways over central nervous system pathways, contributing to the drug's selective pharmacodynamic profile.

Dosage and Administration Information

How to Use Allerfex (Fexofenadine)

Allerfex is administered exclusively by the oral route, utilizing the available forms: oral tablet, oral suspension, and the oral disintegrating tablet (ODT). Dosing is specified based on age and health status.

Standard Dosing Regimens

The standard adult dose (ages 12 years and older) is either 180 mg once daily (QD) or 60 mg twice daily (BID). For children aged 6 to 11 years, the dose is typically 30 mg twice daily (BID). Pediatric administration for those 6 months to less than 2 years of age uses the 15 mg twice daily (BID) dose of the oral suspension. Administration occurs on a fixed daily schedule, and generally, no dose adjustment is necessary for patients with hepatic impairment.

Administration Conditions

Administration Constraint Official Label Requirement
With Food Conventional tablets and suspension can be taken without regard to meals. ODTs should be taken on an empty stomach.
Timing Take with water; avoid taking with fruit juices (e.g., grapefruit, orange, or apple), as this may decrease absorption.
Antacid Separation Must be taken at least two hours apart from aluminum or magnesium-containing antacids to prevent reduced bioavailability.
Renal Impairment For adults 12 years and older with renal impairment, the dose must be reduced to 60 mg once daily (QD).

Procedural Note

The Oral Disintegrating Tablet (ODT) should be placed on the tongue to dissolve and should not be broken, chewed, or swallowed whole. The medication is typically used on an ongoing basis during periods of symptomatic exposure, without a predefined short-term cycle.

Recent Clinical Evidence

Allerfex: Recent Clinical Evidence

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research was conducted on Seasonal Allergic Rhinitis (SAR, or hay fever) and Perennial Allergic Rhinitis (PAR). The primary evidence relies on short-term, double-blind, placebo-controlled clinical trials examining outcomes related to physical discomfort, including changes in overall symptom scores (TSS) and individual metrics like sneezing, nasal itching, and itchy or watery eyes. When comparing the active compound to a placebo, findings describe patterns observed in the studies where measurements of symptom scores evolved differently in the observed populations. Long-term effects are not fully established for this indication as follow-up durations were limited (typically 2–8 weeks).

Evidence for Use in Chronic Idiopathic Urticaria (Chronic Hives)

Research settings explored Chronic Idiopathic Urticaria (CIU), a type of persistent hives, through controlled, short-term clinical trials. These studies examined outcomes related to physical discomfort, specifically the daily mean severity of pruritus (itching) and the change in the number of wheals (hives). When comparing the active compound to placebo, findings describe patterns observed where measurements showed changes. However, findings were mixed regarding the clinical usefulness of escalating the standard study dosage in participants whose symptoms were not fully controlled.

Long-Term Research and Durability of Effect

Most core regulatory evidence is derived from studies observing responses over defined time intervals that are relatively short. The follow-up durations were limited in many trials. Consequently, long-term effects are not fully established in the research record, meaning there is limited information for long-term outcomes regarding the sustained consistency of measured changes over many months.

Evidence in Special Populations and Subgroups

The medicine was studied for both adults and specific pediatric groups. For allergic rhinitis, clinical trials included children aged 2 years and older. For chronic hives, clinical pharmacology data is available down to 6 months of age. However, data for certain groups remain insufficient, especially for the youngest children with allergic rhinitis and those who are pregnant or breastfeeding. Research on older adults may have modest sample sizes.

What Remains Uncertain: Research Gaps and Limitations

While the evidence base for Allerfex is substantial, several research gaps have been noted. As stated, long-term effects are not fully established because follow-up durations were limited. Additionally, data for certain groups remain insufficient, especially for the youngest children. Researchers sometimes noted that the evidence quality varies across studies, with some earlier trials showing moderate methodological limitations.

Frequently Asked Questions (FAQ)

Common questions about Allerfex (FAQ)

Q: How long does it usually take for Allerfex to start working?

A: Studies and official information indicate that the onset of relief has been observed rapidly. Effects are often noted within two hours of administration, with some clinical studies describing the onset of symptom relief as quick as one hour.

Q: How long does the effect of Allerfex usually last?

A: Regulatory documents describe this medicine as having a long duration of action. The effects of the active ingredient have been noted in studies to persist for up to 24 hours, which supports the common dosing schedules of once-daily or twice-daily use.

Q: What specific drugs are known to have major interactions with Allerfex?

A: Regulatory documents describe interactions with certain medicines that affect drug transporters, such as the antifungal agent Ketoconazole and the antibiotic Erythromycin, which have been observed to increase Allerfex concentrations. The official labeling describes these interactions as having the potential to modify the medicine’s systemic exposure.

Q: Is there any research on Allerfex use during pregnancy or breastfeeding?

A: Official labeling includes specific caution for use during pregnancy, stating that it should be used only if the potential benefit is judged to justify the potential risk to the fetus. The active ingredient is documented to pass into human breast milk, and its use during lactation is typically addressed with caution in official guidance.

Q: What does official guidance say about discontinuing Allerfex?

A: Official guidance describes the medicine as being typically used on an ongoing basis during symptomatic exposure. However, if any unexpected or untoward effects (adverse reactions) occur, discontinuation is advised in official materials.

Q: What information is available regarding blood pressure while taking Allerfex?

A: Official documents do not generally list blood pressure changes as a common adverse effect. However, rare effects that involve heart rhythm, such as palpitations (fast or irregular heartbeat) and tachycardia, are documented in official safety information.

Q: How is Allerfex administered for individuals with liver issues?

A: Official guidance indicates that dosage adjustment is not typically required for patients with hepatic (liver) impairment. This is because the medicine’s primary clearance method is not substantially altered by changes in liver function, unlike the process for kidney impairment.

Q: Can Allerfex be used for chronic, long-term conditions?

A: The medicine is officially indicated for conditions that are described as chronic, such as Chronic Idiopathic Urticaria (CIU), which refers to persistent hives. Clinical trials have observed the tolerability of the medicine for long-term use, specifically for periods up to 6 to 12 months at approved dosages.

Q: What information is available regarding the use of Allerfex in children?

A: Extensive official information is available on its use in children, with established pediatric dosing. For instance, its use is approved for seasonal allergic rhinitis in children 2 years and older, and for chronic hives in children as young as 6 months of age.

Q: Does Allerfex affect mental focus or concentration?

A: Official mechanistic descriptions note that the medicine has limited ability to cross the blood-brain barrier. This property is associated with a lower likelihood of effects on mental focus or concentration compared to some other types of antihistamines.

Q: Why is Allerfex sometimes used for conditions other than just seasonal allergies?

A: Regulatory documents specify two primary indications for its use. In addition to providing relief for symptoms associated with Seasonal Allergic Rhinitis (hay fever), it is also used for the treatment of Chronic Idiopathic Urticaria (chronic hives).

Q: Does Allerfex contain gluten or common allergens?

A: Official documents provide information on ingredients, noting that some specific dosage forms, such as the orally disintegrating tablet (ODT), contain phenylalanine. Information regarding other specific common allergens like gluten depends on the detailed excipient list for the particular product formulation.

Q: What is the recommended period of time to use Allerfex?

A: Official guidance describes the medication as being typically used on an ongoing basis during periods of symptomatic exposure. Clinical trials, which establish the evidence base, have observed the use of the medicine for periods ranging from a few weeks up to 12 months.

Q: Do any official documents describe potential long-term risks of Allerfex use?

A: Official safety profiles and long-term clinical trial data, which have assessed use for up to 12 months, do not specifically list long-term risks. The official focus is on the profile of known adverse events and their frequencies.

Q: What are the reasons someone might be ineligible to use Allerfex?

A: Official documents define conditions for caution or ineligibility, primarily through contraindications, such as a known hypersensitivity to the active ingredient. Conditional use or caution is also advised for certain groups, including older adults, those with kidney or liver impairment, and those who are pregnant or breastfeeding.

Q: Are there any published clinical trials on Allerfex that patients can look up?

A: Information related to clinical trials for fexofenadine is often registered and publicly accessible. These studies can typically be searched for through government-sponsored registries, such as those maintained by the National Institutes of Health (NIH).

Q: Why are there different strengths or versions of Allerfex available?

A: Different strengths are made available to address the specific, officially approved dosing requirements. These requirements vary across patient populations, such as children in specific age groups, and for different indications.

Q: Does Allerfex affect sleep patterns?

A: The official safety profile includes rare documented effects such as insomnia and other sleep disorders. These are classified as Post-Marketing Reports, meaning their frequency is not precisely known based on initial clinical trials.

Q: Can Allerfex interact with herbal supplements?

A: Official interaction summaries focus on documented drug-drug and drug-food interactions (e.g., specific antacids and fruit juices). Comprehensive interaction information is not always provided for all herbal supplements in the official labeling.

Q: What is the mechanism by which Allerfex helps with allergy symptoms?

A: The medicine works by functioning as a selective histamine blocker. Its mechanism involves blocking the activity of histamine at peripheral H1 receptors, which is the substance the body releases during an allergic response that triggers symptoms like sneezing and itching.

Q: What information is available regarding alcohol use while taking Allerfex?

A: Official product information does not list alcohol as a formal contraindication. However, it is often noted in patient materials that alcohol consumption may worsen effects such as dizziness or headache, which are documented common side effects of the medicine.

Q: Does Allerfex help with allergy-related skin rashes?

A: The medicine has an official indication for the treatment of uncomplicated skin manifestations of Chronic Idiopathic Urticaria (chronic hives). Hives are a specific type of allergic skin rash.

Q: What is the evidence regarding Allerfex for indoor versus outdoor allergies?

A: Research evidence has been gathered for both types of allergic triggers. Official indications cover Seasonal Allergic Rhinitis (SAR), which is commonly associated with outdoor allergens, and Perennial Allergic Rhinitis (PAR), which is often associated with indoor allergens.

Q: Do official documents mention any potential for dependence with Allerfex?

A: The official safety profile and regulatory reviews do not include reports of drug dependence or abuse potential for the active ingredient. This is a consideration often reviewed when medicines are moved to over-the-counter status.

How should Allerfex be stored and disposed of?

How to Store and Dispose of Allerfex (Fexofenadine Hydrochloride)

Allerfex tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The medicine requires protection from excessive moisture and must be kept away from direct light. It is essential to keep the product from freezing.

Storage and Handling Requirements

  • Temperature: Store between 20°C and 25°C.
  • Protection: Guard against excessive moisture and direct light.
  • Safety: The medicine must be kept out of reach of children and should not be used if the carton or seals are torn or opened.

Disposal of Unused Medicine

Unused or expired Allerfex should be disposed of by utilizing a community drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed container before being thrown into the household trash. The medication must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allerfex found in:

A-Z Index: